Research and Development Reports. 5.3.1 ViroPharma shall keep complete and accurate records of its activities conducted under Section 5.1.1 of this Agreement and the results thereof. Within *** (***) days after the end of each calendar year until the First Commercial Sale in the United States of a Product, ViroPharma shall prepare and provide Halozyme with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date of such report, to develop and obtain regulatory approvals to market Products.
Research and Development Reports. 5.3.1 Intrexon shall keep complete and accurate records of its activities conducted under Section 5.1.1 of this Agreement and the results thereof. Within [*****] days after the end of each calendar year until the First Commercial Sale in the United States of a Product, Intrexon shall prepare and provide Halozyme with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date of such report, to develop and obtain regulatory approvals to market Products.
Research and Development Reports. Each party shall keep complete and accurate records of its activities conducted under this Agreement and the results thereof. Within [**] after the end of each [**] following the end of the Research Program Term, each party shall prepare and provide the other party with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date with respect to the development and/or commercialization of Products.
Research and Development Reports. Each Party shall keep the JDC reasonably informed regarding the progress and results of Development activities for Optioned Molecules and Optioned Products, including by providing (a) […***…] reports in reasonable detail of results versus goals (as such goals are set forth in the applicable R&D Plan and Budget) as, in the case of each Party, is typically generated by such Party with respect to its product research and development efforts and (b) any information with respect to Independent Activities required to be provided pursuant to Section 7.3(c).
Research and Development Reports. After the term of the Research Program, and assuming exercise of the Option, within [*] after the end of each [*], PSMA shall prepare and provide ABX with a reasonably detailed written report of the activities conducted under this Agreement, including, without limitation, the general results, status and potential timing of research, preclinical and clinical testing and manufacture of Products, any anticipated IND filings for Products, and any anticipated filings of any BLA and/or similar foreign marketing application for Products. All such reports shall be Confidential Information of PSMA, unless included within a Confidentiality Exception. [*] CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION
Research and Development Reports. Bxxxxx shall keep complete and accurate records of its activities conducted under this Agreement and the results thereof. Within thirty (30) days after the end of each June, Bxxxxx shall prepare and provide Halozyme with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such date of such report to develop and obtain regulatory approvals to market Products in the Territory.
Research and Development Reports. Within [**] days following the end of each calendar year during the term of this Agreement, Biodel shall prepare and deliver to Aegis a written report which shall (a) describe, in reasonable detail, Biodel’s efforts to research and develop Products during such year, and (b) disclose the results thereof achieved during such year, including without limitation any undisclosed Aegis Inventions. The report and contents of any such report shall be owned exclusively by Biodel and Aegis shall treat the report and its contents as Confidential Information of Biodel consistent with Section 8 of this Agreement.
Research and Development Reports. AVI shall keep (or cause to be kept) complete and accurate records of its research, development and commercialization activities under this Agreement. AVI shall maintain (or cause to be maintained) such records in sufficient detail, and in accordance with good scientific practices. AVI shall keep ABX fully informed as to its research, development and commercialization activities hereunder. Without limiting the foregoing, within thirty (30) days of the end of each calendar quarter, AVI shall provide to ABX a reasonably detailed written report regarding such research, development and commercialization activities and the status thereof.
Research and Development Reports. Company shall keep complete and accurate records of its activities conducted under Sections 5.1 and 5.2, and the results thereof. Within [***] after the end of each calendar year until the First Commercial Sale in the United States of a Product, Company shall prepare and provide Halozyme with a reasonably detailed written report of the activities conducted under this Agreement for every Product and the results thereof, through such date of such report, to develop and obtain Regulatory Approvals to market Products. 5.4
Research and Development Reports. Except as set forth in Section 3.5(c)(v) (with respect to [***]) or Section 4.7(c)(viii) (with respect to Optioned Products for which Arcus has exercised its opt-out), each Party shall keep the JDC reasonably informed regarding the progress and results of Development activities for Optioned Molecules and Optioned Products, including by providing [***].
